There are currently 970 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and C S Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: St. Joseph Mercy Hospital, Ann Arbor, Michigan +1 locations
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers
NCT05159427
Recruiting
In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study is to evaluate the in vivo drug dissolution and systemic absorption of modified release formulations of the BCS Class II drug Glipizide by direct sampling of stomach and small intestinal luminal content, blood, urine and feces. Expanding current knowledge of drug dissolution in vivo will help to establish physiologically relevant in vitro models predictive of drug dissolution.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Human Gastrointestinal Physiology Data
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Cryoablation for Monomorphic Ventricular Tachycardia
NCT05675865
Recruiting
The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Sustained VT
Register for Updates
A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease
NCT05849012
Recruiting
The goal of this study is to learn about a low sulfur diet in patients with Crohn's disease. Study participants will be randomized to receive a low sulfur diet or usual diet for 8 weeks. Participants will work with study nutritionists and receive dietary educational materials. Participants will attend 2 in-person visits as well as 6 phone visits during the study. In addition, subjects will undergo testing, including a test to measure rectal sensation, a test to look for small intestinal bacteria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Crohn's Disease in Remission
Register for Updates
Ultrasound-detectable Endotracheal Tube: a Feasibility Study
NCT05941013
Recruiting
The researchers are studying whether special features make it easier to see if the breathing tube is in the correct place. It is hoped that the investigational device will enable more accurate placement (depth and trachea vs. esophagus).
Gender:
ALL
Ages:
Between 6 months and 42 months
Trial Updated:
01/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cardiac Catheterization, Endotracheal Tube
Register for Updates
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423
Recruiting
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) dise... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Exparel Injection for Postoperative Orbital Pain
NCT02381353
Recruiting
After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Michigan Kellogg Eye Institute, Ann Arbor, Michigan
Conditions: Pain, Postoperative
Register for Updates
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
01/22/2025
Locations: Upsher-Smith Clinical Trial Site #2, Ann Arbor, Michigan
Conditions: Migraine Disorders
Register for Updates
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06109181
Recruiting
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/22/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Register for Updates
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
NCT06524635
Recruiting
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradeni... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor, Michigan
Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Register for Updates
Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis
NCT06721572
Recruiting
Transcutaneous Electrical Acustimulation (TEA) is a noninvasive acupuncture method that can be self-administered at home without needles. TEA transmits a weak electrical current using electrodes placed at acupoints and has shown to safely reduce pain in other gastrointestinal conditions. This study will help elucidate if TEA is effective in treating abdominal pain in patients with painful chronic pancreatitis (CP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Chronic Pancreatitis, Pancreatitis
Register for Updates